Acquired secondary RAS mutation in BRAFV600E mutated thyroid cancer patients treated with BRAF inhibitors.

Acquired secondary RAS mutation in BRAFV600E mutated thyroid cancer patients treated with BRAF inhibitors. Thyroid. 2020 Mar 26;: Authors: Cabanillas M, Dadu R, Iyer PC, Wanland KB, Busaidy N, Ying AK, Gule-Monroe M, Wang JR, Zafereo M, Hofmann MC Abstract The BRAFV600E mutation is the most common driver mutation in papillary thyroid cancer (PTC) and anaplastic thyroid cancer (ATC). This mutation is considered actionable and, for BRAFV600E-mutated ATC, a BRAF inhibitor (dabrafenib) in combination with a MEK inhibitor (trametinib) is FDA approved. BRAF inhibitors have also shown efficacy in BRAFV600E-mutated PTC. However, as with all targeted therapies, resistance to these drugs eventually occurs. It is essential that we understand the mechanisms of resistance to the BRAF inhibitors in thyroid cancer in order develop future strategies to effectively treat these patients and improve survival. Herein, we present 4 cases of thyroid cancer patients treated with selective BRAF inhibitors who developed a RAS mutation in addition to the BRAFV600E mutation at progression. Similar to the melanoma experience, the emergence of RAS mutations appears to act as a mechanism of resistance to BRAF inhibitors in thyroid cancers. PMID: 32216548 [PubMed - as supplied by publisher]
Source: Thyroid : official journal of the American Thyroid Association - Category: Endocrinology Tags: Thyroid Source Type: research

Related Links:

Obul Reddy Bandapalli Non-medullary thyroid cancer (NMTC) is a common endocrine malignancy with a genetic basis that has yet to be unequivocally established. In a recent whole-genome sequencing study of five families with occurrence of NMTCs, we shortlisted promising variants with the help of bioinformatics tools. Here, we report in silico analyses and in vitro experiments on a novel germline variant (p.V29L) in the highly conserved oligonucleotide/oligosaccharide binding domain of the Protection of Telomeres 1 (POT1) gene in one of the families. The results showed a reduction in telomere-bound POT1 levels in the muta...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Contributors : Anuhar Chaturvedi ; Razif Gabdoulline ; Michael HeuserSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensMutations in the enzymes IDH1 and IDH2 have been identified in a wide variety of tumors like glioma, chondrosarcoma, thyroid cancer, lymphoma, melanoma, and in acute myeloid leukemia. Mutated IDH1/2 produces the metabolite 2-hydroxyglutarate (2HG), which interferes with epigenetic regulation of gene expression, and thus may promote tumorigenesis. Data for IDH1 inhibitors show that 30-40% of AML patients respond to monotherapy with a median duration of response of 8 mont...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research
Contributors : Anuhar Chaturvedi ; Razif Gabdoulline ; Michael HeuserSeries Type : Methylation profiling by genome tiling arrayOrganism : Homo sapiensMutations in the enzymes IDH1 and IDH2 have been identified in a wide variety of tumors like glioma, chondrosarcoma, thyroid cancer, lymphoma, melanoma, and in acute myeloid leukemia. Mutated IDH1/2 produces the metabolite 2-hydroxyglutarate (2HG), which interferes with epigenetic regulation of gene expression, and thus may promote tumorigenesis. Data for IDH1 inhibitors show that 30-40% of AML patients respond to monotherapy with a median duration of response of 8 months, su...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Methylation profiling by genome tiling array Homo sapiens Source Type: research
Conclusions: Since its introduction, PERCIST 1.0 has been increasingly used in many clinical trials and prospective studies, with variable reporting of metabolic response and survival data. In general, it appears PERCIST response is associated with longer PFS and survival though the heterogeneity of disease, scan timing and therapies make data pooling difficult. Prospective inclusion of the PERCIST 1.0 criteria in clinical trials using FDG, with baseline, early monitoring, and end of therapy scans could inform cancer clinical trials. Support: 5U01CA140204-04 Reference: 1. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST...
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: NET and Others II Source Type: research
Adjuvant therapy with PD-1 inhibitors for resected Stage III/IV melanoma reduces the risk of recurrence by 40 –50% and is now a standard of care. Immune-related adverse events occurred in approximately 37% of patients in the pivotal trials, 10–15% were severe (grade III–IV). Endocrine toxicities were common and mostly irreversible. Thyroid toxicity occurred in 15–20% of patients, hypophysitis (2.2% ), insulin-dependent diabetes mellitus (1%) and adrenalitis (1%). Revision of the American Joint Committee on Cancer staging system (version 8) has resulted in a significant improvement in prognosis ...
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Current Perspective Source Type: research
AbstractTo date, the genes involved in familial non-medullary thyroid cancer (FNMTC) remain poorly understood, with the exception of syndromic cases of FNMTC. It has been proposed that germline mutations in telomere-related genes, such asPOT1, described in familial melanoma might also predispose individuals to thyroid cancer, requiring further research. We aimed to identify germline mutations inPOT1 in selected FNMTC families (with at least three affected members) without a history of other cancers or other features, and to describe the clinical characteristics of these families. Sequencing of the 5 ′UTR and coding r...
Source: Hormones and Cancer - Category: Cancer & Oncology Source Type: research
CONCLUSIONS: Acquired overt thyroid toxicity and above median ATAb levels during anti-PD-1 treatment are associated with improved PFS and OS. Additionally, our results suggest that ATAb levels at baseline are of clinical relevance for PFS and OS. PMID: 32151195 [PubMed - as supplied by publisher]
Source: Thyroid : official journal of the American Thyroid Association - Category: Endocrinology Tags: Thyroid Source Type: research
Locally advanced NMSC is an uncommon disease characterized by a lack of robust data. Classical outcomes cited for T4 NMSC treated with definitive RT are 50% 5y LC. Most publications describing this therapy are from the pre-IMRT era. Simultaneous with major advancements in RT technology (and resultant improved outcomes across disease sites with the ability to dose escalate), T staging has evolved dramatically. In AJCC 6, a T2 NMSC was defined as tumor>2 cm but5 cm; and T4 as invading deep extradermal structures (cartilage, skeletal muscle, or bone).
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Non-squamous Cell Malignancies of the Head and Neck: thyroid, sarcomas, skin cancers, salivary gland and sinus cancers Source Type: research
Sinonasal mucosal melanoma is an aggressive cancer with high mortality, due in part to the significant proportion of patients who develop distant metastases. The standard of care is surgical resection followed by post-operative radiotherapy. Recently, immunotherapy has been added as adjuvant treatment. Identifying patients at increased risk of distant metastasis is important for both management and prognostic reasons. Calculation of tumor volume (TV) has been described in other head and neck cancer types to assist with predicting disease progression and survival.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Non-squamous Cell Malignancies of the Head and Neck: thyroid, sarcomas, skin cancers, salivary gland and sinus cancers Source Type: research
ConclusionThese data support the concept that among most tumor types at least some individual cancers may benefit from treatment with immune checkpoint inhibitors.
Source: Cellular Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Endocrinology | Melanoma | Skin Cancer | Thyroid | Thyroid Cancer